A Review on Recent Advances in Drug Development and Pharmacotherapeutic Approaches for Obesity

Journal Title: Journal of Medical Science And clinical Research - Year 2014, Vol 2, Issue 6

Abstract

Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a risk to health. A crude population measure of obesity is the body mass index (BMI) . A person with a BMI of 30 or more is generally considered obese. A person with a BMI equal to or more than 25 is considered overweight. Obesity is a well-established risk factor for hypertension, hyperlipidemia, type II diabetes, coronary heart disease, stroke, obstructive sleep apnea, asthma, orthopedic disorders, and certain cancers. Despite this risk, the prevalence of obesity continues to increase worldwide, and there is a growing demand for safe and effective antiobesity drugs. Previous antiobesity drugs or anorexigens, particularly centrally acting agents, have poor safety records. Life-threatening safety issues led to the withdrawal of aminorex in 1968, fenfluramine and dexfenfluramine in 1997, and phenyl propanolamine in 2000. Many of the safety issues, such as valvulopathy with fenfluramine and pulmonary arterial hypertension with aminorex, were initially not predicted by routine preclinical toxicology studies. . Meridian(Sibutramine ) was approved by FDA in 1987,Xenical (orlistat) was approved by FDA in 1999, Recently Qsymia (phentermine & topiramate), Belviq(lorcaserin) was approved by FDA in 2012. This review covers the current state of antiobesity drugs and their safety concerns, and highlights new therapeutic targets and also highlights the threats associated with the surgical treatment of obesity as how liposuction surgery recently claim life of JNTU assistant professor.

Authors and Affiliations

Ayesha Siddiqua

Keywords

Related Articles

Proposed Diagnostic Scoring System to Predict Difficult Laparoscopic Cholecystectomy

Background: One of the most common laparoscopic surgeries performed by the general surgeons all over the world is laparoscopic cholecystectomy (LC). Due to various intraoperative difficulties, it is important for a surge...

Efficacy of Ozone Neucleoplasty against Physiotherapy in Cases of Chronic Discogenic Low Back Pain

Objectives: Efficacy of ozone neucleoplasty against physiotherapy in cases of chronic discogenic low back pain. Methods: This is an open level prospective study, involving patients with chronic low back pain of more than...

Prevalence of Gestational Diabetes Mellitus among Cohort of Pregnant Women Registered in Primary Health Center

Background: Gestational Diabetes Mellitus (GDM) is an important public health problem in India. The prevalence of GDM is constantly on the rise, globally. Women with GDM are at increased risk for adverse obstetric and pe...

Estimation of Matrix Metalloproteinases and their Tissue Inhibitors in Urine to Ascertain Noninvasive tools for Detecting Prostate Cancer

Prostatic biopsy, though the gold standard investigation for prostate malignancy, often leads to unnecessary investigation with several complications. Our aim was to find out the cut off values, sensitivity, specificity...

Prescription Patterns of Psychotropic Drugs and Non-Adherence in Patients with Schizophrenia

Context - Polypharmacy, rational or irrational, in psychiatry is a common phenomenon. One needs to understand various clinical and pharmaco-socio-economic factors associated to deal with it. Non adherence to treatment in...

Download PDF file
  • EP ID EP205947
  • DOI -
  • Views 93
  • Downloads 0

How To Cite

Ayesha Siddiqua (2014). A Review on Recent Advances in Drug Development and Pharmacotherapeutic Approaches for Obesity. Journal of Medical Science And clinical Research, 2(6), 1299-1313. https://europub.co.uk./articles/-A-205947